Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes

Open access
Iannantuoni, Francesca, M. de Marañon, Aranzazu, Diaz-Morales, Noelia, Falcon, Rosa, Bañuls, Celia, Abad-Jimenez, Zaida, Victor, Victor M., Hernandez-Mijares, Antonio, Rovira-Llopis, Susana · 2019 · Journal of Clinical Medicine

Abstract

Sodium–glucose co-transporter 2 inhibitors (iSGLT2) have been linked to a considerable reduction in cardiovascular risk in patients with type 2 diabetes (T2D), but the precise molecular mechanisms are still elusive. We aimed to evaluate the effects of the iSGLT2 empagliflozin on systemic inflammation and its potential antioxidant properties. This is an observational, prospective follow-up study of a cohort of fifteen patients with T2D who received 10 mg/day of empagliflozin according to standard clinical care. Measures at baseline, 12 and 24 weeks were taken. Metabolic and anthropometric parameters were evaluated. Production of mitochondrial superoxide, glutathione content, and glutathione s-reductase and catalase mRNA levels were measured in leukocytes. Serum levels of myeloperoxidase, hs-CRP and IL-10 were determined. In addition to decreased body weight and reduced glucose and HbA1c levels, we observed a reduction in superoxide production in leukocytes of diabetic patients and increased glutathione content, prominently after 24 weeks of empagliflozin treatment. Leukocyte expression of glutathione s-reductase and catalase, and serum levels of IL-10 were enhanced at 24 weeks of empagliflozin treatment. Concomitantly, reduced hs-CRP and myeloperoxidase levels were seen. This study provides evidence of the antioxidant and anti-inflammatory properties of empagliflozin treatment in humans, which may contribute to its beneficial cardiovascular effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm8111814

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Empagliflozin effect on glucose metabolism. Blood glucose (A) and HbA1c levels (B) at 12 and at 24 weeks of treatment with empagliflozin 10 mg/day. Abbreviations: EMPA, empagliflozin; HbA1c %, glycated hemoglobin. * p < 0.05 vs. type 2 diabetes baseline.
Figure 1 Empagliflozin effect on glucose metabolism. Blood glucose (A) and HbA1c levels (B) at 12 and at 24 weeks of treatment with empagliflozin 10 mg/day. Abbreviations: EMPA, empagliflozin; HbA1c %, glycated hemoglobin. * p < 0.05 vs. type 2 diabetes baseline.CC BY · PubMed Central
Figure 2 Effect of empagliflozin treatment on oxidative stress parameters and antioxidant enzymes. Mitochondrial superoxide production (A), GSH content (B) and mRNA expression of the antioxidant enzymes GSR (C) and CAT (D) in human leukocytes at 12 and 24 weeks of empagliflozin treatment. Data were normalized to fluorescence at baseline. The values of the relative gene expression were normalized to baseline mRNA expression levels and calculated using the 2−ΔΔCT method. Abbreviations: EMPA, empagliflozin; MTX, MitoSOX Red mitochondrial superoxide indicator; CMFDA, 5-chloromethylfluorescein diacetate; GSH, glutathione, GSR, glutathione S-reductase; CAT, catalase. * p < 0.05, ** p < 0.05 vs. type 2 diabetes baseline. Representative fluorescence microscopy images are shown.
Figure 2 Effect of empagliflozin treatment on oxidative stress parameters and antioxidant enzymes. Mitochondrial superoxide production (A), GSH content (B) and mRNA expression of the antioxidant enzymes GSR (C) and CAT (D) in human leukocytes at 12 and 24 weeks of empagliflozin treatment. Data were normalized to fluorescence at baseline. The values of the relative gene expression were normalized to baseline mRNA expression levels and calculated using the 2−ΔΔCT method. Abbreviations: EMPA, empagliflozin; MTX, MitoSOX Red mitochondrial superoxide indicator; CMFDA, 5-chloromethylfluorescein diacetate; GSH, glutathione, GSR, glutathione S-reductase; CAT, catalase. * p < 0.05, ** p < 0.05 vs. type 2 diabetes baseline. Representative fluorescence microscopy images are shown.CC BY · PubMed Central
Figure 3 Assessment of inflammatory parameters; serum hs-CRP (A), MPO (B) and IL-10 (C) levels at baseline, 12 and 24 weeks of treatment. Abbreviations: EMPA, empagliflozin; hs-CRP, high-sensitive C-reactive protein; MPO, myeloperoxidase; IL-10, interleukin 10. * p < 0.05 compared with type 2 diabetes baseline.
Figure 3 Assessment of inflammatory parameters; serum hs-CRP (A), MPO (B) and IL-10 (C) levels at baseline, 12 and 24 weeks of treatment. Abbreviations: EMPA, empagliflozin; hs-CRP, high-sensitive C-reactive protein; MPO, myeloperoxidase; IL-10, interleukin 10. * p < 0.05 compared with type 2 diabetes baseline.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 166

Metadata

Authors
Iannantuoni, F., M. de Marañon, A., Diaz-Morales, N., Falcon, R., Bañuls, C., Abad-Jimenez, Z., Victor, V. M., Hernandez-Mijares, A., & Rovira-Llopis, S.
Affiliations
  • Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (ES)
  • Service of Endocrinology and Nutrition, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2019-11-01
Volume
8
Issue
11
Pages
1814
ISSN
2077-0383 (ISSN-L)
OpenAlex
W2988212132
Cited by
166
References
47
Citations by year
2026: 12 · 2025: 31 · 2024: 26 · 2023: 25 · 2022: 35 · 2021: 23 · 2020: 13
FWCI
14.40
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Gredos (University of Salamanca) (publishedVersion, cc-by-nc-nd)
  • Hispana (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Instituto de Salud Carlos III (PI16/1083, PI18/00932, CIBERehd CB06/04/0071, FI17/00126, FI14/00125, FI17/00144, CES10/030)
  • Conselleria d'Educació, Investigació, Cultura i Esport (GRISOLIAP/2016/015)
  • Ministerio de Economía y Competitividad (PTA2017-14355I)
  • European Regional Development Fund (A way to build Europe)
  • Menarini S.A. (unrestricted grant)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Keywords
empagliflozin, SGLT2 inhibitors, type 2 diabetes, systemic inflammation, antioxidant response, leukocytes, mitochondrial superoxide, glutathione, glutathione reductase, catalase, myeloperoxidase, C-reactive protein, IL-10, cardiovascular risk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. https://app.cochat.ai/papers/10.3390/jcm8111814
The paper
Iannantuoni, F., M. de Marañon, A., Diaz-Morales, N., Falcon, R., Bañuls, C., Abad-Jimenez, Z., Victor, V. M., Hernandez-Mijares, A., & Rovira-Llopis, S. (2019). The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. Journal of Clinical Medicine. https://doi.org/10.3390/jcm8111814

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.